Literature DB >> 1325068

RU486 in depression.

K R Krishnan1, D Reed, W H Wilson, W B Saunders, J C Ritchie, C B Nemeroff, B J Carroll.   

Abstract

RU486 is a synthetic glucocorticoid antagonist. The authors used RU486 to examine the hypothesis that the elevated plasma cortisol and ACTH in patients is due to suprahypophyseal stimulation of the anterior pituitary. Seven patients and matched controls were studied before and after the administration of RU486. RU486 produced an increase in HPA activity in depressed patients. Thus providing support for the hypothesis that there is increased suprahypophyseal stimulation of the anterior pituitary.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325068     DOI: 10.1016/0278-5846(92)90109-r

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.

Authors:  Nunzio Pomara; Raymundo T Hernando; Corazon B de la Pena; John J Sidtis; Thomas B Cooper; Steven Ferris
Journal:  Neurochem Res       Date:  2006-05-23       Impact factor: 3.996

Review 2.  Corticosteroid receptor antagonists: a current perspective.

Authors:  W Sutanto; E R de Kloet
Journal:  Pharm World Sci       Date:  1995-03-24

3.  Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

Authors:  B E Murphy; D Filipini; A M Ghadirian
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

4.  Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications.

Authors:  Peter Gallagher; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.